Viruses and the OAS-RNase L Pathway
A special issue of Viruses (ISSN 1999-4915).
Deadline for manuscript submissions: closed (30 September 2019) | Viewed by 18503
Special Issue Editors
Interests: coronavirus pathogenesis; murine coronavirus; human respiratory coronaviruses; MERS-CoV; SARS-CoV-2; common CoVs; viral antagonism of innate immunity; OAS/RNase L; endogenous dsRNA induced pathogenesis; Zika virus
Special Issue Information
Dear Colleagues,
OAS-RNase L is a potent interferon-regulated antiviral pathway that severely limits the pathogenesis of many different types of viruses. Upon sensing viral (non-self) dsRNA, OASs produce 2’,5’-oligoadenylates (2-5A) that bind to and cause the activation of RNase L. RNase L then cleaves both the host and viral single-stranded RNA, thereby limiting protein production, virus replication and spread, and causing apoptosis. Recent and exciting advances emphasize the importance of OAS-RNase L in antiviral innate immunity. Some of these studies reveal how viruses evolved many strategies to antagonize OAS-RNase L, including sequestering dsRNA from OAS, degrading 2-5A by viral- or host-encoded enzymes or directly inhibiting RNase L. Other studies extend beyond the antiviral state into cellular responses to host (self) dsRNA induced by genetic or epigenetic events. This unique and first-of-its-kind issue on OAS-RNase L will contribute to our understanding of how this remarkable innate immune pathway impacts human health in the context of viral and genetic diseases and cancer.
Prof. Dr. Susan Weiss
Prof. Dr. Robert H. Silverman
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Ribonuclease L
- oligoadenylate synthetase
- 2’,5’-oligoadenylates
- viral antagonists
- phosphodiesterases
- endogenous dsRNA
- antiviral pathways
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.